Estrogen/progesterone - Transdermal Delivery Solutions
Alternative Names: Estrogen + Progesterone - Transdermal Delivery Solutions; Estrogen/progesterone spray - Transdermal Delivery Solutions; Estrogen/progesterone TDS®Latest Information Update: 24 Aug 2023
At a glance
- Originator Transdermal Delivery Solutions Corp
- Developer St. Bartholomews Hospital; Transdermal Delivery Solutions Corp
- Class Gonadal steroid hormones; Hormonal contraceptives; Hormonal replacements
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Menopausal syndrome
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Menopausal syndrome in USA (Transdermal) (Transdermal Delivery Solutions Corp pipeline, August 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Menopausal-syndrome in USA (Transdermal, Spray)
- 27 May 2016 Estrogen/progesterone transdermal is still in non-clinical development for Menopausal syndrome (Company website - May 2016)